Literature DB >> 21344196

Hypogonadism in DM1 and its relationship to erectile dysfunction.

Giovanni Antonini1, Alessandro Clemenzi, Elisabetta Bucci, Emanuela De Marco, Stefania Morino, Antonella Di Pasquale, Pamela Latino, Gilda Ruga, Andrea Lenzi, Nicola Vanacore, Antonio F Radicioni.   

Abstract

Myotonic dystrophy type 1 (DM1) is characterized by both a premature appearance of age-related phenotypes and multiple organ involvement, which affects skeletal and smooth muscle as well as the eye, heart, central nervous system, and endocrine system. Although erectile dysfunction (ED) is a frequent complaint in patients with DM1, it has not been investigated in great depth. Hypogonadism, which is reported to be one of the physical causes of ED in the general population, frequently occurs in DM1. We planned this case-control study to evaluate the relationship between hypogonadism, as defined by the sexual hormone profile (FSH, LH, testosterone (T) and prolactin) and ED, as assessed by means of an internationally validated self-administered questionnaire (IIEF). DM1 patients had significantly increased mean levels of both gonadotropins (FSH and LH) (p < 0.0001) and a reduced mean level of T (p < 0.0001) when compared to controls. Twelve patients were eugonadic (normal LH, T, and FSH), while 18 displayed hormonal evidence of hypogonadism, characterized by tubular failure (increased FSH) in all the subjects and associated with interstitial failure in 14 subjects: seven with primary hypogonadism (increased LH and reduced T) and seven with compensated hypogonadism (increased LH and normal T). Patients with hormonal evidence of interstitial failure had a larger CTG expansion (p = 0.008), longer disease duration (p = 0.013), higher grade of disease (p = 0.004) and lower erectile function score (p = 0.02) than eugonadic patients. Impotence occurred in 13/14 hypogonadic patients with interstitial failure and in 5/12 eugonadic patients (p = 0.017, OR = 18.2).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21344196     DOI: 10.1007/s00415-011-5914-3

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  36 in total

1.  Effects of a novel selective androgen receptor modulator on dexamethasone-induced and hypogonadism-induced muscle atrophy.

Authors:  Amanda Jones; Dong-Jin Hwang; Ramesh Narayanan; Duane D Miller; James T Dalton
Journal:  Endocrinology       Date:  2010-06-09       Impact factor: 4.736

2.  Randomized controlled trial of testosterone in myotonic dystrophy.

Authors:  R C Griggs; S Pandya; J M Florence; M H Brooke; W Kingston; J P Miller; J Chutkow; B E Herr; R T Moxley
Journal:  Neurology       Date:  1989-02       Impact factor: 9.910

3.  Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study.

Authors:  Abdelouahid Tajar; Gianni Forti; Terence W O'Neill; David M Lee; Alan J Silman; Joseph D Finn; György Bartfai; Steven Boonen; Felipe F Casanueva; Aleksander Giwercman; Thang S Han; Krzysztof Kula; Fernand Labrie; Michael E J Lean; Neil Pendleton; Margus Punab; Dirk Vanderschueren; Ilpo T Huhtaniemi; Frederick C W Wu
Journal:  J Clin Endocrinol Metab       Date:  2010-02-19       Impact factor: 5.958

Review 4.  Characterisation, prevalence, and consultation rates of erectile dysfunction.

Authors:  John Dean
Journal:  Clin Cornerstone       Date:  2005

5.  Erectile dysfunction in myotonic dystrophy type 1 (DM1).

Authors:  Giovanni Antonini; Alessandro Clemenzi; Elisabetta Bucci; Stefania Morino; Matteo Garibaldi; Micaela Sepe-Monti; Franco Giubilei; Giuseppe Novelli
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

Review 6.  Glucocorticoid-induced myopathy.

Authors:  Rosa Maria Rodrigues Pereira; Jozélio Freire de Carvalho
Journal:  Joint Bone Spine       Date:  2010-05-14       Impact factor: 4.929

7.  Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy.

Authors:  J Mathieu; H Boivin; D Meunier; M Gaudreault; P Bégin
Journal:  Neurology       Date:  2001-02-13       Impact factor: 9.910

Review 8.  Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting.

Authors:  Norleena P Gullett; Gautam Hebbar; Thomas R Ziegler
Journal:  Am J Clin Nutr       Date:  2010-02-17       Impact factor: 7.045

9.  Clinical and hormonal aspects of male hypogonadism in myotonic dystrophy.

Authors:  I Mastrogiacomo; G Bonanni; E Menegazzo; C Santarossa; E Pagani; M Gennarelli; C Angelini
Journal:  Ital J Neurol Sci       Date:  1996-02

10.  Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations.

Authors:  C Wang; E Nieschlag; R Swerdloff; H M Behre; W J Hellstrom; L J Gooren; J M Kaufman; J-J Legros; B Lunenfeld; A Morales; J E Morley; C Schulman; I M Thompson; W Weidner; F C W Wu
Journal:  Eur J Endocrinol       Date:  2008-11       Impact factor: 6.664

View more
  9 in total

1.  Fluid intelligence, traits of personality and personality disorders in a cohort of adult KS patients with the classic 47, XXY karyotype.

Authors:  D Liberato; S Granato; D Grimaldi; F M Rossi; N Tahani; D Gianfrilli; A Anzuini; A Lenzi; G Cavaggioni; A F Radicioni
Journal:  J Endocrinol Invest       Date:  2017-04-11       Impact factor: 4.256

2.  Tadalafil improves lean mass and endothelial function in nonobese men with mild ED/LUTS: in vivo and in vitro characterization.

Authors:  Antonio Aversa; Simona Fittipaldi; Davide Francomano; Viviana M Bimonte; Emanuela A Greco; Clara Crescioli; Luigi Di Luigi; Andrea Lenzi; Silvia Migliaccio
Journal:  Endocrine       Date:  2017-01-30       Impact factor: 3.633

3.  Hypogonadism Associated with Cyp19a1 (Aromatase) Posttranscriptional Upregulation in Celf1 Knockout Mice.

Authors:  Gaella Boulanger; Marie Cibois; Justine Viet; Alexis Fostier; Stéphane Deschamps; Sylvain Pastezeur; Catherine Massart; Bernhard Gschloessl; Carole Gautier-Courteille; Luc Paillard
Journal:  Mol Cell Biol       Date:  2015-07-13       Impact factor: 4.272

4.  Study of anti-Müllerian hormone levels in patients with Myotonic Dystrophy Type 1. Preliminary results.

Authors:  Manuela Ergoli; Massimo Venditti; Raffaele Dotolo; Esther Picillo; Sergio Minucci; Luisa Politano
Journal:  Acta Myol       Date:  2017-12-01

5.  Hormonal and metabolic gender differences in a cohort of myotonic dystrophy type 1 subjects: a retrospective, case-control study.

Authors:  M Spaziani; A Semeraro; E Bucci; F Rossi; M Garibaldi; M A Papassifachis; C Pozza; A Anzuini; A Lenzi; G Antonini; A F Radicioni
Journal:  J Endocrinol Invest       Date:  2019-11-30       Impact factor: 4.256

6.  Vitamin D deficiency in myotonic dystrophy type 1.

Authors:  Chiara Terracciano; Emanuele Rastelli; Maria Morello; Monica Celi; Elisabetta Bucci; Giovanni Antonini; Ottavia Porzio; Umberto Tarantino; Rossella Zenobi; Roberto Massa
Journal:  J Neurol       Date:  2013-06-11       Impact factor: 4.849

7.  From mini-puberty to pre-puberty: early impairment of the hypothalamus-pituitary-gonadal axis with normal testicular function in children with non-mosaic Klinefelter syndrome.

Authors:  M Spaziani; S Granato; N Liberati; F M Rossi; N Tahani; C Pozza; D Gianfrilli; G Papi; A Anzuini; A Lenzi; L Tarani; A F Radicioni
Journal:  J Endocrinol Invest       Date:  2020-05-06       Impact factor: 4.256

8.  Muscular dystrophies at different ages: metabolic and endocrine alterations.

Authors:  Oriana Del Rocío Cruz Guzmán; Ana Laura Chávez García; Maricela Rodríguez-Cruz
Journal:  Int J Endocrinol       Date:  2012-06-03       Impact factor: 3.257

9.  Blood Transcriptome Profiling Links Immunity to Disease Severity in Myotonic Dystrophy Type 1 (DM1).

Authors:  Sylvia Nieuwenhuis; Joanna Widomska; Paul Blom; Peter-Bram A C 't Hoen; Baziel G M van Engelen; Jeffrey C Glennon
Journal:  Int J Mol Sci       Date:  2022-03-12       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.